

1 **IL-8 as a potential link between aging and impaired influenza antibody responses in older**
2 **adults**

3 **Huy Quang Quach¹, Krista M. Goergen², Diane E. Grill², Inna G. Ovsyannikova¹, Gregory**
4 **A. Poland¹, and Richard B. Kennedy^{1,*}**

5 ¹Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.

6 ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.

7 *Correspondence: kennedy.rick@mayo.edu (R.B.K.)

8

9

10

11

12

13

14

15

16

17

18 **Abstract**

19 **Background.** Antibody responses to MF59-adjuvanted (MF59Flu) and high-dose (HDFlu)
20 influenza vaccines have been well-characterized in older adults, yet corresponding cellular
21 response data remain limited.

22 **Methods.** Blood samples were collected from 106 MF59Flu recipients and 112 HDFlu recipients
23 before vaccination (Day 0), and on Days 1, 8, and 28 post-vaccination. Antibody responses were
24 assessed on Days 0, 8, and 28 using a hemagglutination inhibition (HAI) assay. Eight pro-
25 inflammatory cytokines and chemokines, including IFN- α 2a, IFN- γ , IP-10, MCP-1, MIP-1 α , IL-
26 1 β , IL-6, IL-8, were quantified from PBMCs collected on Days 0 and 1 following stimulation with
27 live influenza A/H3N2 virus using a multiplex assay. Associations between cytokine/chemokine
28 levels and HAI titers were examined, along with the effect of sex, age, body mass index (BMI),
29 and cytomegalovirus infection status.

30 **Results.** Vaccine type (MF59Flu or HDFlu), sex, BMI and cytomegalovirus infection did not
31 significantly impact cytokine and chemokine levels. However, age was positively correlated with
32 IL-8 level on Day 1 ($r = 0.24$, $p = 0.0003$) as well as the change in IL-8 levels from Day 1 to Day
33 0 ($r = 0.16$, $p = 0.021$). Notably, the change in IL-8 levels was negatively associated with peak
34 antibody responses at Day 28 ($r = -0.15$, $p = 0.026$).

35 **Conclusion.** Our findings underscore IL-8 as a potential link between aging and impaired antibody
36 responses to influenza vaccination in older adults, suggesting that IL-8 inhibition could be a
37 promising molecular intervention to improve immunogenicity and efficacy of influenza vaccines
38 in this high-risk population.

39 **Keywords:** Influenza vaccine, MF59Flu, HDFlu, cytokines, chemokines, older adults, antibody

40 **1. Introduction**

41 Older adults (≥ 65 years) are particularly vulnerable to severe influenza illness, accounting for up
42 to 85% of deaths and 70% of hospitalizations related to seasonal flu [1]. This heightened risk is
43 primarily attributed to immunosenescence, the functional decline of T and B cells with age [2]. To
44 address this, MF59-adjuvanted (MF59Flu) and high-dose (HDFlu), two enhanced influenza
45 vaccines, have been recommended for this population. While most studies suggest that the two
46 vaccines offer similar effectiveness in older adults [3-5], some studies favor MF59Flu [6], and
47 others support HDFlu [7]. These discrepancies highlight the challenges of assessing vaccine
48 efficacy and emphasize the need for further research to identify factors that may influence these
49 differential outcomes.

50 Conventionally, influenza vaccine effectiveness is assessed by measuring the titer of neutralizing
51 hemagglutination inhibiting antibodies or by differentiating influenza-specific memory T cells,
52 with antibody considered as the primary correlate of protection for influenza [8]. However,
53 effective activation of T and B cells is primarily orchestrated by the local cytokine and chemokine
54 environment, which is shaped by the activation of innate immune cells. This cytokine and
55 chemokine milieu can have paradoxical effects on host defense against influenza [9, 10]. On the
56 one hand, cytokines and chemokines can exert antiviral activities by inhibiting influenza virus
57 replication [11, 12] and promoting T and B cell immunity [13, 14]. Conversely, excessive secretion
58 of pro-inflammatory cytokines and chemokines have been linked to severe disease outcomes [15-
59 21]. In response to influenza vaccination, studies have shown that increases in TNF- α response
60 [22] and decreases in IL-8 production [23] are correlated with improved antibody responses in
61 vaccine responders. However, vaccine non-responders and responders had comparable levels of
62 IFN- γ , IL-6, and IL-10 [24]. These mixed results underscore the need for further research to clarify

63 the role of these cytokines and chemokines in influenza immunity. This is especially important in
64 older adults, who are often affected by “inflammaging”, a condition characterized by elevated level
65 of inflammatory markers with age [25, 26].

66 In this study, we isolated PBMCs from MF59Flu and HDFlu recipients and characterized cytokine
67 and chemokine responses in these cells upon *in vitro* stimulation with influenza virus.
68 Additionally, we examined the potential impact of vaccine type, sex, age, body mass index (BMI),
69 and cytomegalovirus (CMV) infection status on cytokine and chemokine profiles.

70 **2. Methods**

71 The methods used in this study are identical or similar to the methods used in our previous
72 publications [27-29].

73 **2.1. Study participants**

74 This study was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB# 17-
75 010601) and conducted in accordance with the Declaration of Helsinki. All study participants
76 provided written informed consent prior to enrollment in this study.

77 A total of 250 participants (≥ 65 years) were recruited from Olmsted County, MN, and the
78 surrounding areas for this study. Participants were randomly assigned to receive either the MF59-
79 adjuvanted inactivated influenza vaccine (MF59Flu, marketed as Fluad®) or high-dose inactivated
80 influenza vaccine (HDFlu, marketed as Fluzone®). Both vaccines are trivalent, containing three
81 viral strains: i) H1N1 (A/Michigan/45/2015/pdm09-like strain), ii) H3N2 (A/Singapore/INFIMH-
82 16-0019/2016-like strain), and iii) influenza B lineage (Colorado/06/2017-like Victoria lineage
83 strain). Vaccination histories and health status were documented for all participants. Additionally,

84 body mass index (BMI) was calculated from height and weight data collected on all study
85 participants. Participants who exhibited symptoms associated with influenza infection during the
86 study period were excluded from data analysis.

87 **2.2. Processing blood samples**

88 Blood samples were collected from each participant at four timepoints: prior to the receipt of
89 vaccination (Day 0) and on Days 1, 8, and 28 after vaccination. Serum and peripheral blood
90 mononuclear cells (PBMCs) were isolated from blood samples using a standard protocol
91 established in our laboratory [28]. Both serum samples and PBMCs were stored at -80 °C until
92 further analysis.

93 **2.4. Hemagglutination inhibition assay**

94 We performed a hemagglutination inhibition (HAI) assay against the influenza A/H3N2 virus
95 (A/Singapore/INFIMH-16-0019/2016/H3N2 strain) using sera collected at Days 0, 8, and 28. HAI
96 results from Day 0 and Day 28 sera from this study cohort were partially summarized in our earlier
97 publication [27]. In the current study, we investigated the associations between cytokine and
98 chemokine concentrations secreted by PBMCs sampled at Day 0 and Day 1 and the HAI titers at
99 Days 0, 8, and 28. The coefficient of variation for the HAI assay in our laboratory was 2.9% [30].

100 **2.5. Cytokine and chemokine assays**

101 Cytokine and chemokine secretion was quantified using multiplex electrochemiluminescence-
102 based kits (Meso Scale Diagnostics, Rockville, MD). Briefly, 2×10^5 live PBMCs sampled at Day
103 0 and Day 1 were plated in triplicates in each well of a 96-well round bottom plate. The cells were
104 then incubated under one of following conditions: i) RPMI media alone (unstimulated), ii) live

105 influenza A/H3N2 virus (A/Singapore/INFIMH-16-0019/2016-like strain; multiply of infection or
106 MOI=0.5) in RPMI media, or iii) phytohemagglutinin (PHA; 10 µg/mL) in RPMI media. After an
107 18-hour incubation at 37 °C with 5% CO₂, the cell culture supernatants were collected and stored
108 at -80°C until for batched measurements. For the multiplex assay, supernatants were diluted 2-fold
109 with assay diluent and assayed for the following cytokines and chemokines: IFN-α2a, IFN-γ, IL-
110 1β, IL-6, IL-8, interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein
111 (MCP)-1, and macrophage inflammatory protein (MIP)-1α. The assay was conducted according
112 to the manufacturer's protocol. The plates were read, and the results were analyzed at the Mayo
113 Clinic Immunochemical Core Laboratory. According to the manufacturer, the coefficient of
114 variation for each analyte was <20%.

115 **2.6. Measurement of cytomegalovirus (CMV) IgG**

116 Serum level of CMV IgG was measured using a Bio-Rad CMV IgG EIA kit (catalog no. 25177),
117 with results reported as a sample index. The sample index was then used to categorize results as
118 either CMV seronegative or seropositive, following the manufacturer's instruction. The assay had
119 an intra-assay coefficient of variation (CV) of 8.3% and inter-assay CV of 9.5%, according to the
120 manufacturer.

121 **2.7. Statistical analysis**

122 The Wilcoxon rank-sum test was used to assess the differences in age, weight, height, BMI, and
123 analyte concentrations between two vaccine groups (MF59Flu and HDFlu). The differences in
124 categorical variables (sex, ethnicity, and race) were evaluated by Pearson's Chi-squared test. The

125 association between analyte concentrations and variables such as age, BMI, and HAI titer was
126 assessed by Spearman's rank correlation.

127 **3. Results**

128 **3.1. Characteristics of study cohort**

129 The demographic characteristics of this cohort were partially reported in Table 1 of our earlier
130 publication [27, 29]. Briefly, we recruited 250 older adults (≥ 65 years) who received either
131 MF59Flu or HDFlu. Of these, 32 participants were excluded from the current study due to not
132 receiving the vaccination ($n = 9$), incomplete study visits for blood draws ($n = 7$), or insufficient
133 PBMCs for the assays ($n = 16$). The remaining cohort ($n = 218$) consisted of 106 MF59Flu
134 recipients and 112 HDFlu recipients (**Table 1, Figure 1**). Both vaccine groups (MF59Flu and
135 HDFlu) were comparable in demographic characteristics, including sex, age, ethnicity, race, and
136 BMI (**Table 1**).

137 **3.2. PBMCs from MF59Flu and HDFlu groups generate comparable levels of cytokines and** 138 **chemokines**

139 PBMCs sampled at Day 0 and Day 1 were incubated with live A/H3N2 virus overnight and the
140 concentrations of eight cytokines and chemokines (IFN- $\alpha 2a$, IFN- γ , IP-10, MCP-1, MIP-1 α , IL-
141 1 β , IL-6, and IL-8) were measured in the cell culture supernatant. Under unstimulated conditions,
142 PBMCs from both Day 0 and Day 1 secreted these analytes at background levels (**Supplementary**
143 **Figure S1**). However, upon stimulation with A/H3N2 virus, the concentration of these analytes
144 increased over 10-fold (**Supplementary Figure S1**). Despite this robust response to viral
145 stimulation, analyte concentrations were comparable between MF59Flu and HDFlu groups at
146 either Day 0 or Day 1 (**Supplementary Figure S2**). We also did not observe any influence of sex

147 on the change (Day 1 – Day 0) of analyte concentrations after vaccination (**Supplementary Figure**
148 **S3**).

149 **3.3. IL-8 concentration is associated with age**

150 At Day 0, there were no significant correlations between age and the concentrations of analytes (p
151 >0.05) (**Figure 2**). However, age was positively correlated with IL-8 concentration at Day 1 ($r =$
152 0.24 , $p = 0.00028$), as well as the change (Day 1 – Day 0) in IL-8 concentration ($r = 0.16$, $p =$
153 0.021) (**Figure 2A**). Additionally, age was positively correlated with IL-1 β concentrations at Day
154 1 ($r = 0.14$, $p = 0.042$), but not the change in IL-1 β concentration after vaccination ($r = 0.097$, $p =$
155 0.15) (**Figure 2B**). No other significant correlations were found between age and the
156 concentrations of the remaining analytes (**Figure 2**).

157 **3.4. Associations between HAI and cytokine or chemokine secretion**

158 We measured HAI titers in serum samples collected at Days 0, 8, and 28, and examined the
159 correlation between these titers and the change (Day 1 – Day 0) in analyte concentrations (**Figure**
160 **3, Supplementary Figure S4**). IP-10 exhibited a positive correlation with HAI titer ($r = 0.16$, $p =$
161 0.024) at Day 0, but not at Day 1. The change in IL-8 concentration did not significantly correlate
162 with the HAI titers at Day 0 ($r = -0.037$, $p = 0.59$) although a negative trend was noticed at Day 8
163 ($r = -0.13$, $p = 0.056$). A significant negative association was observed between the decrease in IL-
164 8 concentration at Day 1 compared to Day 0 and HAI titer at Day 28 ($r = -0.15$, $p = 0.0026$) (**Figure**
165 **3**). No significant correlations were found between changes in the concentration of other analytes
166 and HAI titer (**Supplementary Figure S4**).

167 **3.5. CMV infection and BMI did not influence cytokine/chemokine responses**

168 Prior cytomegalovirus (CMV) infection, a recognized marker of immunosenescence, has been
169 linked to diminished immune responses to influenza vaccination [31]. In our cohort, we measured
170 CMV-specific IgG in serum to determine CMV serostatus, identifying 91 CMV seronegative and
171 125 CMV seropositive recipients, as well as 2 recipients with CMV equivocal results (neither
172 negative nor positive). Regardless of vaccine type (MF59Flu or HDFlu), the concentrations of the
173 cytokine and chemokine analytes were comparable between CMV seronegative and CMV
174 seropositive recipients (**Supplementary Figure S5**).

175 Additionally, no significant correlation was observed between body mass index (BMI) and the
176 concentration of the analytes on both Day 0 and Day 1 (**Supplementary Figure S6**).

177 **4. Discussion**

178 Impaired immune responses in older adults (≥ 65 years) have led to the recommendation to use of
179 either MF59Flu or HDFlu for this population. While humoral (antibody) responses to these
180 vaccines are well-documented, less is known about the cellular responses, particularly regarding
181 cytokine and chemokine production. In this study, we aimed to characterize early cellular immune
182 responses by analyzing cytokine and chemokine production in PBMCs isolated from recipients of
183 MF59Flu and HDFlu before (Day 0) and one day after vaccination (Day 1). This approach provides
184 insights into early immune activation and potential differences between these two vaccine
185 formulations in older adults. Additionally, we examined how sex, age, BMI, and CMV infection
186 status might influence cytokine and chemokine responses. Understanding how these factors affect
187 immune responses could inform strategies to optimize vaccination efficacy in this vulnerable
188 population.

189 MF59Flu and HDFlu enhance immune responses through distinct mechanisms. Specifically,
190 MF59Flu utilizes an oil-in-water emulsion adjuvant MF59, which rapidly induces the generation
191 of inflammatory cytokines and chemokines, recruiting multiple innate immune cells to the site of
192 injection [32]. In contrast, HDFlu contains a four-fold increase in antigen, compared to standard-
193 dose influenza vaccines, but does not include any adjuvants [33]. Despite these differences, our
194 study revealed surprisingly similar cytokine and chemokine response profiles between the two
195 vaccine groups (**Supplementary Figures S1-S3**). Moreover, these response profiles were not
196 significantly influenced by key demographic and clinical factors, such as sex, BMI, and CMV
197 infection status (**Supplementary Figures S3, S5, S6**). While this finding contradicted our initial
198 hypothesis, it is consistent with previous findings of similar vaccine effectiveness between
199 MF59Flu and HDFlu [3-7]. These results suggest a potential correlation between the early
200 production of pro-inflammatory cytokines and chemokines and subsequent antibody responses.
201 Future studies comparing the efficacy of novel vaccine candidates against current influenza
202 vaccines could leverage cytokine and chemokine profiles as early biomarkers, measurable as soon
203 as one day post-vaccination, to predict vaccine effectiveness.

204 Previous studies have attributed the impaired responses to influenza vaccination in older adults
205 primarily to the functional declines of both B and T cells [34-36]. However, effective activation
206 of these adaptive immune cells after vaccination requires a supportive cytokine and chemokine
207 milieu, largely produced by innate immune cells. In this study, we observed a positive association
208 between age and IL-8 secretion post-vaccination (**Figure 2**). More notably, the early change in IL-
209 8 concentration from Day 0 to Day 1 was negatively associated with HAI titers at Day 28 (**Figure**
210 **3**), suggesting a potential link between aging and diminished antibody responses in older adults to
211 influenza vaccination. Previous studies have also reported a decrease in serum levels of IL-8

212 following influenza vaccination or infection [23, 37, 38]. In line with these findings, we observed
213 a decline in IL-8 levels secreted by PBMCs one day after vaccination (**Supporting Figures S1**
214 **and S2**). This consistent reduction in IL-8 suggests that suppressing IL-8 production may play a
215 pivotal role in enhancing the efficacy influenza vaccines in older adults.

216 The strength of our study lies in its well-controlled design. Our study cohort, consisting of
217 recipients of both MF59Flu and HDFlu, had comparable demographic characteristics, which
218 helped minimize potential impacts of these factors on cytokine and chemokine responses. Indeed,
219 we did not observe any significant impacts of demographic factors, such as sex or BMI, on
220 cytokine and chemokine responses (**Supplementary Figures S5 and S6**). However, we also
221 acknowledge several limitations. First, we focused on antibody responses against the influenza
222 A/H3N2 virus due to its particularly detrimental effects on older adults, but antibody responses to
223 other vaccine strains may differ. Therefore, future studies should extend these findings by
224 evaluating humoral responses to all influenza strains included in the vaccine. Second, the source
225 of IL-8 remains to be fully elucidated. While IL-8 can be produced by multiple immune cell types,
226 our previous findings suggested that monocytes, in collaboration of activated platelets, may be the
227 primary source of IL-8 [39]. Further studies are needed to identify the specific sources and cell
228 subsets responsible for maintaining a high baseline IL-8 level in older adults and the subsequent
229 reduction in IL-8 post-vaccination. Understanding these cellular mechanisms could provide new
230 targets to enhance vaccine-induced immune responses to influenza in older adults.

231 In summary, this study characterized cytokine and chemokine responses in *in vitro* stimulated
232 PBMCs from recipients of the MF59Flu and HDFlu vaccines. Our results revealed a positive
233 association between age and IL-8 concentration, which was negatively correlated with antibody
234 responses. Although the precise cellular source of IL-8 remains to be determined, our findings

235 suggest a potential link between age and impaired immune responses in older adults to influenza
236 vaccine. This connection could serve as a potential target for molecular interventions aimed at
237 enhancing influenza vaccine effectiveness in this high-risk population.

238 **Author Contributions**

239 HQQ analyzed data and wrote the first draft of the manuscript. IGO, GAP, and RBK were involved
240 in the conceptualization of the study. KMG and DEG performed statistical analyses. RBK and
241 GAP were involved in the funding acquisition and project administration. All authors edited,
242 revised, and approved submitted version of the manuscript.

243 **Funding**

244 This research was funded by the National Institute of Allergy and Infectious Diseases of the
245 National Institutes of Health with grant number R01AI132348, the Center for Influenza Vaccine
246 Research for High-Risk Populations (CIVR-HRP) with contract number 75N93019C00052
247 (CIVIC). The content of this study is solely the responsibility of the authors and does not
248 necessarily represent the official views of the National Institute of Health.

249 **Data Availability Statement**

250 All data included in this study are presented as figures and tables and available from the
251 corresponding author upon reasonable request.

252 **Acknowledgments**

253 We would like to thank all participants in this study. We are grateful to the financial support from
254 NIAID and CIVR-HRP.

255 **Conflicts of Interest**

256 Dr. Poland is the chair of a safety evaluation committee for novel investigational vaccine trials
257 being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to
258 AiZtech; Emergent Biosolutions; GlaxoSmithKline; Invivyd; Janssen Global Services, LLC;
259 Merck & Co. Inc.; Moderna; Novavax; and Syneos Health. Dr. Poland holds patents related to
260 vaccinia, influenza, and measles peptide vaccines. Dr. Poland is an adviser to the White House and
261 World Health Organization on COVID-19 vaccines and monkeypox, respectively. Drs. Poland,
262 Kennedy, and Ovsyannikova have received grant funding and royalties from ICW Ventures for
263 preclinical studies on a peptide-based COVID-19 vaccine. Drs. Poland, Kennedy, and
264 Ovsyannikova have a pending patent related to COVID-19 peptide-based vaccines. Dr. Kennedy
265 also offers consultative advice on vaccine development to Merck & Co. and Sanofi Pasteur. These
266 activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are
267 conducted in compliance with Mayo Clinic Conflict of Interest policies. Other co-authors declare
268 no competing interests.

269 **References**

- 270 1. <https://www.cdc.gov/flu/highrisk/65over.htm>.
- 271 2. McElhaney JE. Influenza vaccine responses in older adults. *Ageing Res Rev* **2011**; 10:379-88.
- 272 3. Domnich A, de Waure C. Comparative effectiveness of adjuvanted versus high-dose seasonal
273 influenza vaccines for older adults: a systematic review and meta-analysis. *Int J Infect Dis* **2022**;
274 122:855-63.
- 275 4. Ku JH, Rayens E, Sy LS, et al. Comparative Effectiveness of Licensed Influenza Vaccines in
276 Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza
277 Season Among Adults ≥ 65 Years of Age. *Clinical Infectious Diseases* **2024**:ciae375.
- 278 5. McGovern I, Chastek B, Bancroft T, et al. Relative vaccine effectiveness of MF59-adjuvanted
279 vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza
280 hospitalizations during the 2017-2020 influenza seasons. *Int J Infect Dis* **2024**; 146:107160.

- 281 6. Boikos C, McGovern I, Ortiz JR, Puig-Barberà J, Versage E, Haag M. Relative Vaccine
282 Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza
283 Seasons in the United States. *Vaccines*. Vol. 10, **2022**.
- 284 7. van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose versus
285 adjuvanted influenza vaccine: A retrospective cohort study. *Vaccine* **2020**; 38:372-9.
- 286 8. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly:
287 a quantitative review. *Vaccine* **2006**; 24:1159-69.
- 288 9. Tavares LP, Teixeira MM, Garcia CC. The inflammatory response triggered by Influenza virus:
289 a two edged sword. *Inflammation Research* **2017**; 66:283-302.
- 290 10. Guo X-zJ, Thomas PG. New fronts emerge in the influenza cytokine storm. *Seminars in*
291 *Immunopathology* **2017**; 39:541-50.
- 292 11. García-Sastre A, Biron CA. Type 1 Interferons and the Virus-Host Relationship: A Lesson in
293 Détente. *Science* **2006**; 312:879-82.
- 294 12. Wu W, Metcalf JP. The Role of Type I IFNs in Influenza: Antiviral Superheroes or
295 Immunopathogenic Villains? *J Innate Immun* **2020**; 12:437-47.
- 296 13. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I
297 interferons. *Nat Rev Immunol* **2012**; 12:125-35.
- 298 14. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic
299 cells induce plasma cell differentiation through type I interferon and interleukin 6. *Immunity* **2003**;
300 19:225-34.
- 301 15. Almansa R, Anton A, Ramirez P, et al. Direct association between pharyngeal viral secretion
302 and host cytokine response in severe pandemic influenza. *BMC Infect Dis* **2011**; 11:232.
- 303 16. Arankalle VA, Lole KS, Arya RP, et al. Role of host immune response and viral load in the
304 differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. *PLoS*
305 *One* **2010**; 5.
- 306 17. Christian LM, Porter K, Karlsson E, Schultz-Cherry S. Proinflammatory cytokine responses
307 correspond with subjective side effects after influenza virus vaccination. *Vaccine* **2015**; 33:3360-
308 6.
- 309 18. Gao R, Bhatnagar J, Blau DM, et al. Cytokine and chemokine profiles in lung tissues from
310 fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in
311 pathogenesis. *Am J Pathol* **2013**; 183:1258-68.
- 312 19. Martinez-Ocaña J, Olivo-Diaz A, Salazar-Dominguez T, et al. Plasma cytokine levels and
313 cytokine gene polymorphisms in Mexican patients during the influenza pandemic
314 A(H1N1)pdm09. *J Clin Virol* **2013**; 58:108-13.
- 315 20. Teijaro JR. The role of cytokine responses during influenza virus pathogenesis and potential
316 therapeutic options. *Curr Top Microbiol Immunol* **2015**; 386:3-22.
- 317 21. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation
318 in severe cases of pandemic H1N1 2009 influenza virus infection. *Clin Infect Dis* **2010**; 50:850-9.

- 319 22. Kang M, Lin F, Jiang Z, et al. The impact of pre-existing influenza antibodies and
320 inflammatory status on the influenza vaccine responses in older adults. *Influenza Other Respir*
321 *Viruses* **2023**; 17:e13172.
- 322 23. Ramakrishnan A, Althoff KN, Lopez JA, Coles CL, Bream JH. Differential serum cytokine
323 responses to inactivated and live attenuated seasonal influenza vaccines. *Cytokine* **2012**; 60:661-
324 6.
- 325 24. Krakauer T, Russo C. Serum cytokine levels and antibody response to influenza vaccine in the
326 elderly. *Immunopharmacol Immunotoxicol* **2001**; 23:35-41.
- 327 25. Ferrucci L, Fabbri E. Inflammaging: chronic inflammation in ageing, cardiovascular disease,
328 and frailty. *Nature Reviews Cardiology* **2018**; 15:505-22.
- 329 26. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-
330 metabolic viewpoint for age-related diseases. *Nature Reviews Endocrinology* **2018**; 14:576-90.
- 331 27. Haralambieva IH, Quach HQ, Ovsyannikova IG, et al. T Cell Transcriptional Signatures of
332 Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine
333 in Older Adults. *Viruses* **2022**; 14:2763.
- 334 28. Quach HQ, Chen J, Monroe JM, et al. The influence of sex, BMI, and age on cellular and
335 humoral immune responses against measles after a 3rd dose of MMR vaccine. *J Infect Dis* **2022**.
- 336 29. Quach HQ, Haralambieva IH, Goergen KM, et al. Similar humoral responses but distinct CD4+
337 T cell transcriptomic profiles in older adults elicited by MF59 adjuvanted and high dose influenza
338 vaccines. *Scientific Reports* **2024**; 14:24420.
- 339 30. Zimmermann MT, Kennedy RB, Grill DE, et al. Integration of Immune Cell Populations,
340 mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination:
341 Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations. *Front Immunol* **2017**;
342 8:445.
- 343 31. Derhovanessian E, Maier AB, Hähnel K, McElhaney JE, Slagboom EP, Pawelec G. Latent
344 infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core
345 proteins in the elderly. *J Immunol* **2014**; 193:3624-31.
- 346 32. Ko EJ, Kang SM. Immunology and efficacy of MF59-adjuvanted vaccines. *Hum Vaccin*
347 *Immunother* **2018**; 14:3041-5.
- 348 33. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of High-Dose versus Standard-
349 Dose Influenza Vaccine in Older Adults. *New England Journal of Medicine* **2014**; 371:635-45.
- 350 34. Aiello A, Farzaneh F, Candore G, et al. Immunosenescence and Its Hallmarks: How to Oppose
351 Aging Strategically? A Review of Potential Options for Therapeutic Intervention. *Front Immunol*
352 **2019**; 10:2247.
- 353 35. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human
354 vaccine immune responses. *Immun Ageing* **2019**; 16:25.
- 355 36. Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. *Signal*
356 *Transduction and Targeted Therapy* **2023**; 8:200.
- 357 37. Talaat KR, Halsey NA, Cox AB, et al. Rapid changes in serum cytokines and chemokines in
358 response to inactivated influenza vaccination. *Influenza Other Respir Viruses* **2018**; 12:202-10.

359 38. Tang W, Xie H, Ye Z, et al. Post-vaccination serum cytokines levels correlate with
360 breakthrough influenza infections. *Sci Rep* **2023**; 13:1174.

361 39. Quach HQ, Johnson C, Ekholt K, Islam R, Mollnes TE, Nilsson PH. Platelet-Depletion of
362 Whole Blood Reveals That Platelets Potentiate the Release of IL-8 From Leukocytes Into Plasma
363 in a Thrombin-Dependent Manner. *Frontiers in Immunology* **2022**; 13.


364

365 Table and Figures

366 **Table 1. Demographic characteristics of study cohort.**


Characteristics	MF59Flu (n = 106)	HDFlu (n = 112)	Total (n = 218)	p value
Sex				0.428 ^a
Male (%)	38 (36.8%)	46 (41.1%)	84 (38.5%)	
Female (%)	68 (64.2%)	66 (58.9%)	134 (61.5%)	
Age (years)				0.462 ^b
Median (Q1, Q3)	72 (68.1, 76.6)	71.1 (67.7, 75.4)	71.6 (67.9, 76)	
Ethnicity				0.956 ^a
Non-Hispanic nor Latino	104 (98.1%)	110 (98.2%)	214 (98.2%)	
Hispanic or Latino	2 (1.9%)	2 (1.8%)	4 (1.8%)	
Race				0.303 ^a
Black or African American	1 (0.9 %)	0	1 (0.5%)	
White	105 (99.1%)	112 (100%)	217 (99.5%)	
BMI				0.429 ^b
Median (Q1, Q3)	28.45 (25.26, 31.57)	27.99 (25.05, 31.18)	28.28 (25.13, 31.51)	
CMV infection				
Negative			91	
Equivocal			2	
Positive			125	

367 ^aPearson's Chi-squared test, ^bWilcoxon rank sum test.




368


369 **Figure 1. Study design.** The study cohort included 106 recipients of the MF59-adjuvanted
370 influenza vaccine (MF59Flu) and 112 recipients of the high-dose influenza vaccine (HDFlu).
371 Blood samples were collected prior to vaccination (Day 0) and on Days 1, 8, and 28 post-
372 vaccination. Peripheral blood mononuclear cells (PBMCs) were isolated from the Day 0 and Day
373 1 blood samples and *in vitro* stimulated with live influenza A/H3N2 virus. Production of eight pro-
374 inflammatory cytokines and chemokines (IFN- α 2a, IFN- γ , IL-1 β , IL-6, IL-8, IP-10, MCP-1, MIP-
375 1 α) were quantified in the cell culture supernatants using an MSD multiplex assay. Additionally,
376 serum antibody titers against the A/H3N2 virus were measured in sera collected at Days 0, 8, and
377 28 using the hemagglutination inhibition (HAI) assay. Associations between cytokine/chemokine
378 responses and HAI titers were examined. The impact of key demographic and clinical factors,
379 including age, sex, body mass index (BMI), and cytomegalovirus (CMV) infection status on the
380 cytokine and chemokine profiles was assessed. Created in BioRender.com.



382 **Figure 2. Positive correlation between age and IL-8.** At Day 0, there was no significant
383 correlation between age and IL-8 concentration ($r = 0.035$, $p = 0.61$, Figure 2A). However, age
384 was positively correlated with IL-8 level at Day 1 ($r = 0.24$, $p = 0.00028$) and the change in IL-8
385 level from Day 1 to Day 0 ($r = 0.16$, $p = 0.021$). The correlations between age and the change in
386 the concentration of other analytes were not significant (B-H).




387
388 **Figure 3. Negative correlation between the change in IL-8 secretion level and the HAI titers**
389 **at Day 0, Day 8, and Day 28.** Although there was a trend of negative correlation between the
390 changes in IL-8 level from Day 0 to Day 1 and HAI titer at Day 0 ($r = -0.037$) and Day 8 ($r = -$
391 0.13), these correlations were not statistically significant ($p > 0.05$). The negative correlation
392 between the change in IL-8 and HAI titers at Day 28 were significant.




393

394 **Supplementary Figure S1. Significant changes in the production of cytokines and**
395 **chemokines from *in vitro* stimulated PBMCs.** Abbreviation: unstim = unstimulation (cell
396 cultured in media); stim = H3N2 stimulation.



397


398 **Supplementary Figure S2. Nonsignificant influences of vaccine type (MF59Flu and HDFlu)**
399 **in the production of cytokines and chemokines from in vitro stimulated PBMCs.**



400

401 **Supplementary Figure S3. Nonsignificant influences of sex in the production of cytokines**


402 **and chemokines from in vitro stimulated PBMCs.**



403


404 **Supplementary Figure S4. Nonsignificant correlations between the change in other cytokines**

405 **and chemokines and the HAI titers at Day 0, Day 8, and Day 28.**



406

407 **Supplementary Figure S5. Nonsignificant impacts of CMV infection on the cytokine and**
408 **chemokine responses.**



409

410 **Supplementary Figure S6. Nonsignificant correlations between BMI and the cytokine and**
411 **chemokine responses.**